This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
summary conclusions | 468 |
blood donors | 386 |
blood group | 229 |
blood transfusion | 215 |
whole blood | 195 |
blood donation | 190 |
red blood | 179 |
hev infection | 164 |
virus infection | 131 |
red cell | 130 |
blood components | 122 |
blood products | 120 |
blood cells | 120 |
blood bank | 116 |
blood donor | 103 |
pregnant women | 99 |
hev rna | 97 |
blood cell | 86 |
transfusion reactions | 83 |
risk factors | 74 |
significantly higher | 68 |
chronic hepatitis | 66 |
orf protein | 66 |
platelet concentrates | 66 |
acute hepatitis | 65 |
amino acid | 65 |
capsid protein | 65 |
red cells | 65 |
latex allergy | 63 |
cell culture | 61 |
rna viruses | 61 |
hev strains | 58 |
blood donations | 58 |
transfusion medicine | 58 |
virus replication | 57 |
adverse events | 56 |
hev igg | 55 |
rna polymerase | 54 |
blood supply | 54 |
abstract withdrawn | 53 |
ng ml | 53 |
stem cell | 52 |
performed using | 52 |
public health | 51 |
flow cytometry | 51 |
hev seroprevalence | 49 |
statistically significant | 48 |
cysteine protease | 48 |
respiratory syndrome | 48 |
adverse reactions | 47 |
viral replication | 47 |
room temperature | 46 |
donor selection | 46 |
blood services | 45 |
control group | 45 |
antibody screening | 45 |
general population | 45 |
platelet count | 45 |
macro domain | 44 |
blood banks | 44 |
transplant recipients | 44 |
hev genotypes | 44 |
open reading | 44 |
viral hepatitis | 43 |
present study | 43 |
first time | 43 |
blood product | 43 |
iu ml | 43 |
total number | 42 |
antigen expression | 42 |
time donors | 42 |
high density | 41 |
organ transplant | 41 |
blood samples | 41 |
viral rna | 40 |
dependent rna | 40 |
blood service | 40 |
hemorrhagic fever | 40 |
trima accel | 39 |
national blood | 38 |
significant difference | 38 |
transfusion service | 38 |
monoclonal antibody | 38 |
density multiepitope | 38 |
hematopoietic stem | 37 |
congo hemorrhagic | 37 |
united states | 37 |
cord uid | 37 |
hev replication | 37 |
group system | 37 |
doc id | 37 |
serum samples | 36 |
iron deficiency | 36 |
reading frame | 36 |
ferritin levels | 36 |
cell line | 36 |
clinical trials | 35 |
zoonotic transmission | 35 |
blood collection | 35 |
developing countries | 35 |
infectious diseases | 35 |
repeat donors | 35 |
rhd gene | 34 |
multiepitope protein | 34 |
blood component | 34 |
blood safety | 34 |
clinical practice | 34 |
hev infections | 34 |
clinically significant | 33 |
virus orf | 33 |
age group | 33 |
risk factor | 33 |
nucleic acid | 33 |
protease activity | 33 |
hev protease | 31 |
genotype hev | 31 |
hev orf | 31 |
blood transfusions | 31 |
quality control | 30 |
blood units | 30 |
virus particles | 30 |
female donors | 30 |
cfu ml | 30 |
blood groups | 29 |
binding site | 29 |
health care | 29 |
study period | 29 |
transfusion services | 29 |
high risk | 29 |
immune response | 29 |
rna virus | 29 |
sickle cell | 29 |
amino acids | 29 |
viral macrodomains | 29 |
transfusion reaction | 28 |
may also | 28 |
acute respiratory | 28 |
blood centers | 28 |
lg ml | 28 |
red cross | 28 |
positive samples | 28 |
respiratory viruses | 28 |
genomic dna | 27 |
porcine circovirus | 27 |
hb levels | 27 |
like cysteine | 27 |
syndrome virus | 27 |
porcine reproductive | 27 |
terumo bct | 27 |
nipah virus | 27 |
hev gt | 27 |
developed countries | 27 |
male donors | 27 |
chain reaction | 26 |
low hb | 26 |
results suggest | 26 |
generation sequencing | 26 |
viral genome | 26 |
per year | 26 |
among blood | 26 |
foodborne viruses | 26 |
crystal structure | 26 |
polymerase chain | 26 |
abo blood | 26 |
hemolytic transfusion | 26 |
group antigens | 26 |
sanger sequencing | 25 |
industrialized countries | 25 |
increased risk | 25 |
antiglobulin test | 25 |
fever virus | 25 |
significant differences | 25 |
safe blood | 25 |
encephalomyelitis virus | 25 |
two groups | 25 |
mg ml | 25 |
iron supplementation | 25 |
immunocompromised patients | 25 |
rubella virus | 24 |
platelet function | 24 |
west nile | 24 |
infected cells | 24 |
side effects | 24 |
blood center | 24 |
chronic hev | 24 |
family hepeviridae | 24 |
closely related | 24 |
immune system | 24 |
rhd genotyping | 24 |
autologous blood | 24 |
rbc units | 24 |
chronic infection | 24 |
patients undergoing | 24 |
previous studies | 23 |
two different | 23 |
virus genotype | 23 |
liver transplant | 23 |
schizophrenia patients | 23 |
transfusion safety | 23 |
strand rna | 23 |
cell disease | 23 |
receptor binding | 23 |
complete genome | 23 |
cell lines | 23 |
rhd negative | 23 |
higher risk | 23 |
years old | 23 |
mean age | 23 |
even though | 23 |
clinical symptoms | 22 |
sf cells | 22 |
hb content | 22 |
severe acute | 22 |
bone marrow | 22 |
immune responses | 22 |
world health | 22 |
influenza virus | 22 |
dna samples | 22 |
nile virus | 22 |
human hepatitis | 22 |
hev particles | 22 |
cell transplantation | 22 |
gene expression | 22 |
rabbit hev | 22 |
rbc transfusion | 22 |
column agglutination | 22 |
high prevalence | 22 |
syncytial virus | 21 |
platelet transfusion | 21 |
liver disease | 21 |
hev prevalence | 21 |
respiratory syncytial | 21 |
positive results | 21 |
time pcr | 21 |
hendra virus | 21 |
hemagglutinating encephalomyelitis | 21 |
specific antibodies | 21 |
positive donations | 21 |
retrospective analysis | 21 |
hev genome | 21 |
storage period | 21 |
monoclonal antibodies | 21 |
plasma samples | 21 |
wild boar | 21 |
least one | 21 |
determine whether | 21 |
blood sample | 21 |
health organization | 21 |
platelet content | 21 |
western blot | 20 |
previous study | 20 |
hev igm | 20 |
phylogenetic analysis | 20 |
enteric viruses | 20 |
network analysis | 20 |
donor deferral | 20 |
transfusion therapy | 20 |
transfusion associated | 20 |
age groups | 20 |
genome sequences | 20 |
donor samples | 20 |
plasma units | 20 |
antiviral activity | 20 |
genetic diversity | 20 |
blood management | 20 |
cell units | 20 |
cell surface | 20 |
last years | 20 |
latex gloves | 20 |
orf polyprotein | 20 |
peripheral blood | 20 |
hev antibodies | 20 |
one case | 19 |
stem cells | 19 |
voluntary blood | 19 |
middle east | 19 |
natural rubber | 19 |
clinically relevant | 19 |
culture system | 19 |
sg hev | 19 |
recent years | 19 |
insect cells | 19 |
transmitted infections | 19 |
healthcare workers | 19 |
oral route | 19 |
viral infections | 19 |
significantly lower | 19 |
samples collected | 19 |
papain like | 19 |
cell transfusion | 19 |
liver failure | 19 |
potential risk | 19 |
sectional study | 19 |
university hospital | 19 |
european countries | 19 |
hemolytic disease | 19 |
porcine endogenous | 19 |
liver samples | 19 |
blood grouping | 19 |
previously described | 19 |
results obtained | 19 |
indirect antiglobulin | 18 |
additive solution | 18 |
retrospective study | 18 |
life cycle | 18 |
hiv infection | 18 |
pig farms | 18 |
transmitted non | 18 |
blood volume | 18 |
another study | 18 |
platelet concentrate | 18 |
serum ferritin | 18 |
packed red | 18 |
platelet units | 18 |
reading frames | 18 |
human hev | 18 |
rubber latex | 18 |
enterically transmitted | 18 |
ppk cells | 18 |
united kingdom | 18 |
hev virions | 18 |
reactive results | 18 |
frozen plasma | 17 |
cd cells | 17 |
transfused patients | 17 |
architect i | 17 |
virus infections | 17 |
ae ml | 17 |
infected pigs | 17 |
orf product | 17 |
ribavirin treatment | 17 |
type i | 17 |
recent study | 17 |
animal movements | 17 |
patient blood | 17 |
neutralizing antibodies | 17 |
next generation | 17 |
south africa | 17 |
reference laboratory | 17 |
new donors | 17 |
active site | 17 |
transfusion practices | 17 |
hepatitis virus | 17 |
donor health | 17 |
informed consent | 17 |
hb level | 17 |
rhd positive | 17 |
virus rna | 17 |
binding sites | 17 |
tested using | 17 |
wild rabbits | 17 |
automated blood | 17 |
foodborne outbreaks | 17 |
transplant patients | 17 |
pathogen inactivation | 17 |
hev capsid | 16 |
selection criteria | 16 |
donate blood | 16 |
cell cultures | 16 |
transfusion practice | 16 |
spectra optia | 16 |
serological testing | 16 |
bleeding patients | 16 |
cold storage | 16 |
massive transfusion | 16 |
statistical analysis | 16 |
reference sequences | 16 |
naked hev | 16 |
study showed | 16 |
rhd typing | 16 |
direct contact | 16 |
spectrum antiviral | 16 |
animal models | 16 |
respiratory tract | 16 |
quality assurance | 16 |
bacterial growth | 16 |
factors associated | 16 |
important role | 16 |
plasma exchange | 16 |
enveloped viruses | 16 |
residual risk | 16 |
i sr | 16 |
patients receiving | 16 |
cardiac surgery | 16 |
blood type | 16 |
like particles | 16 |
sequence analysis | 16 |
bacterial contamination | 16 |
blood pressure | 16 |
donor screening | 15 |
growth factor | 15 |
orf encodes | 15 |
truncated orf | 15 |
nucleotide sequence | 15 |
frequently detected | 15 |
recombinant plasmid | 15 |
rna interference | 15 |
escherichia coli | 15 |
orf gene | 15 |
drinking water | 15 |
hbv dna | 15 |
significantly increased | 15 |
pathological changes | 15 |
molecular biology | 15 |
described previously | 15 |
cysteine proteases | 15 |
foodborne transmission | 15 |
regular blood | 15 |
highly conserved | 15 |
renal failure | 15 |
pretransfusion testing | 15 |
viral proteins | 15 |
human health | 15 |
clinical significance | 15 |
wide range | 15 |
six months | 15 |
risk groups | 15 |
donor safety | 15 |
high frequency | 15 |
nervous system | 15 |
iron stores | 15 |
white blood | 15 |
stranded rna | 15 |
fresh frozen | 15 |
platelet yield | 15 |
rhd exon | 15 |
farmed rabbits | 15 |
apheresis platelets | 15 |
syndrome coronavirus | 15 |
group systems | 15 |
hev sequences | 15 |
bact alert | 15 |
hev seropositivity | 14 |
commercially available | 14 |
patients received | 14 |
regular donors | 14 |
fully automated | 14 |
igg antibodies | 14 |
protease inhibitors | 14 |
genomic rna | 14 |
base call | 14 |
also found | 14 |
dong thap | 14 |
central nervous | 14 |
ribose binding | 14 |
virus entry | 14 |
donor recruitment | 14 |
cobe spectra | 14 |
buffy coat | 14 |
replacement therapy | 14 |
hev specific | 14 |
plc prf | 14 |
compatible blood | 14 |
acute viral | 14 |
positive donors | 14 |
tube method | 14 |
pyramidal cells | 14 |
coated vesicles | 14 |
years ago | 14 |
transfusion center | 14 |
viral load | 14 |
donor population | 14 |
year period | 14 |
virus seroprevalence | 14 |
cmv igg | 14 |
platelet products | 14 |
rhd variants | 14 |
viral macro | 14 |
adverse effects | 14 |
animal reservoirs | 14 |
food handlers | 14 |
cd monoclonal | 14 |
platelet transfusions | 14 |
transplant recipient | 14 |
solid organ | 14 |
wild boars | 14 |
therapeutic plasma | 14 |
logistic regression | 14 |
iron overload | 14 |
bedouin arabs | 14 |
previously reported | 14 |
transfusion recipients | 14 |
large number | 14 |
hev genotype | 14 |
case report | 14 |
platelet counts | 14 |
donor blood | 14 |
genetic heterogeneity | 14 |
coding region | 14 |
transfusion transmitted | 14 |
virus transmission | 14 |
iv iron | 14 |
adverse outcomes | 14 |
orf proteins | 14 |
clinical samples | 14 |
group antigen | 14 |
normal rhd | 14 |
infection hepatitis | 14 |
psap motif | 14 |
cultured cells | 14 |
intensive care | 14 |
samples tested | 14 |
iron depletion | 14 |
specific ige | 13 |
encephalitis virus | 13 |
analysis showed | 13 |
plasma membrane | 13 |
dna sequencing | 13 |
hev strain | 13 |
gene deletion | 13 |
structural protein | 13 |
pathogen reduction | 13 |
pegylated interferon | 13 |
high mortality | 13 |
month deferral | 13 |
human strain | 13 |
human monoclonal | 13 |
scd patients | 13 |
extrahepatic manifestations | 13 |
cord blood | 13 |
different blood | 13 |
detection rates | 13 |
spina bifida | 13 |
supply chain | 13 |
study aimed | 13 |
blood loss | 13 |
virus hepatitis | 13 |
antibody identification | 13 |
contaminated water | 13 |
three different | 13 |
protein expression | 13 |
infect humans | 13 |
false positive | 13 |
pg ml | 13 |
results indicate | 13 |
resequencing microarray | 13 |
base calls | 13 |
molecular basis | 13 |
donor return | 13 |
pooled platelet | 13 |
member states | 13 |
pig farm | 13 |
vox sanguinis | 13 |
ag ab | 13 |
prospective study | 13 |
clinical trial | 13 |
pcp domain | 13 |
donor retention | 13 |
rat serum | 13 |
sense rna | 13 |
clinical manifestations | 13 |
food chain | 13 |
infectious disease | 13 |
dromedary camels | 13 |
randomly selected | 13 |
negative control | 13 |
nucleotide sequences | 13 |
cell concentrates | 13 |
viral infection | 13 |
molecular virology | 13 |
cell antigens | 13 |
viral particles | 13 |
virion release | 13 |
infection among | 13 |
allergic reactions | 13 |
heme iron | 13 |
family members | 13 |
major cause | 13 |
cell antibody | 13 |
innate immunity | 13 |
escape mutants | 13 |
hiv ag | 13 |
specific primers | 13 |
antibody detection | 13 |
patient safety | 13 |
nucleic acids | 13 |
epidemiological studies | 12 |
european union | 12 |
endogenous retroviruses | 12 |
binding affinity | 12 |
i will | 12 |
log iu | 12 |
iron status | 12 |
three times | 12 |
class i | 12 |
care workers | 12 |
bamboo rats | 12 |
patients treated | 12 |
vasovagal reactions | 12 |
sporadic cases | 12 |
chikungunya virus | 12 |
mean hb | 12 |
bat hbv | 12 |
risk assessment | 12 |
innate immune | 12 |
fetal rhd | 12 |
hev pcp | 12 |
data analysis | 12 |
saharan africa | 12 |
high incidence | 12 |
vitro quality | 12 |
sublingual immunotherapy | 12 |
differential diagnosis | 12 |
antibody positive | 12 |
culture systems | 12 |
results show | 12 |
human cells | 12 |
kidney cells | 12 |
days post | 12 |
hla antibodies | 12 |
sample size | 12 |
infected individuals | 12 |
treated cells | 12 |
tertiary care | 12 |
control study | 12 |
host range | 12 |
abo typing | 12 |
tissue culture | 12 |
autochthonous hepatitis | 12 |
antiviral drugs | 12 |
standard deviation | 12 |
median age | 12 |
dg gel | 12 |
epithelial cells | 12 |
macro domains | 12 |
animal species | 12 |
host cells | 12 |
circovirus type | 12 |
routine use | 12 |
within days | 12 |
pig liver | 12 |
highly sensitive | 12 |
host cell | 12 |
virus antibodies | 12 |
direct antiglobulin | 12 |
plasma transfusion | 12 |
quality management | 12 |
prt system | 11 |
health status | 11 |
functional domains | 11 |
significantly reduced | 11 |
mm tris | 11 |
respiratory virus | 11 |
huh cells | 11 |
rna genome | 11 |
vesicular stomatitis | 11 |
breast cancer | 11 |
rhd variant | 11 |
new zealand | 11 |
pilot study | 11 |
high throughput | 11 |
multisystemic wasting | 11 |
rbv treatment | 11 |
hla typing | 11 |
two years | 11 |
gtp pools | 11 |
lymph nodes | 11 |
based surveillance | 11 |
plasma dna | 11 |
reactive samples | 11 |
blood processing | 11 |
significant increase | 11 |
single nucleotide | 11 |
reverse transcription | 11 |
data suggest | 11 |
storage time | 11 |
abo genotyping | 11 |
related viruses | 11 |
platelet antigens | 11 |
adverse reaction | 11 |
southern vietnam | 11 |
genotype hepatitis | 11 |
also performed | 11 |
published data | 11 |
many countries | 11 |
transmission routes | 11 |
buffy coats | 11 |
study design | 11 |
expression system | 11 |
cross match | 11 |
systematic review | 11 |
information system | 11 |
also used | 11 |
wasting syndrome | 11 |
primary prevention | 11 |
nonstructural proteins | 11 |
helicase domain | 11 |
human transmission | 11 |
infectious virus | 11 |
samples using | 11 |
inhibitory effect | 11 |
seroprevalence rates | 11 |
infected patients | 11 |
component preparation | 11 |
apheresis platelet | 11 |
blood centres | 11 |
adverse event | 11 |
hiv positive | 11 |
human immunodeficiency | 11 |
electron microscopy | 11 |
molecular typing | 11 |
molecular characterization | 11 |
whole genome | 11 |
blood system | 11 |
infectious agents | 11 |
screening tests | 11 |
pediatric patients | 11 |
treatment failure | 11 |
copies ml | 11 |
subgenomic rna | 11 |
emerging viruses | 11 |
stomatitis virus | 11 |
high level | 11 |
hemoglobin level | 11 |
among first | 11 |
clinical cases | 11 |
highly prevalent | 11 |
mortality rate | 11 |
transmitted via | 11 |
specific sirnas | 11 |
liver transplantation | 10 |
hepatoma cells | 10 |
will also | 10 |
helper type | 10 |
cd count | 10 |
several studies | 10 |
clinical transfusion | 10 |
ex vivo | 10 |
mdck i | 10 |
rbc transfusions | 10 |
disease virus | 10 |
forward type | 10 |
observational study | 10 |
renal replacement | 10 |
hbv infection | 10 |
capsid proteins | 10 |
disease control | 10 |
million donations | 10 |
case reports | 10 |
scrambled sirna | 10 |
may help | 10 |
borne viruses | 10 |
using different | 10 |
human infection | 10 |
rich region | 10 |
preoperative anemia | 10 |
haemolytic transfusion | 10 |
voluntary non | 10 |
blood screening | 10 |
recent syphilis | 10 |
immunodeficiency virus | 10 |
recent report | 10 |
orf sequences | 10 |
gradient centrifugation | 10 |
allele frequencies | 10 |
tube methods | 10 |
recent studies | 10 |
chronic liver | 10 |
screening test | 10 |
gel cards | 10 |
detected variant | 10 |
transfusion related | 10 |
hong kong | 10 |
negative pregnant | 10 |
mortality rates | 10 |
circulatory overload | 10 |
may cause | 10 |
group alleles | 10 |
per unit | 10 |
widely used | 10 |
primary pig | 10 |
screening assays | 10 |
may provide | 10 |
sheep pcs | 10 |
confidence interval | 10 |
bombay phenotype | 10 |
genetically diverse | 10 |
russian federation | 10 |
three months | 10 |
transfusion protocol | 10 |
mononuclear cells | 10 |
also showed | 10 |
ribavirin therapy | 10 |
novel hepatitis | 10 |
fresh produce | 10 |
mammalian cells | 10 |
also known | 10 |
risk group | 10 |
enzymatic activity | 10 |
recombinant hepatitis | 10 |
dengue virus | 10 |
genbank accession | 10 |
units per | 10 |
infected animals | 10 |
viral genomes | 10 |
host factors | 10 |
best hit | 10 |
virus detection | 10 |
alanine aminotransferase | 10 |
four genotypes | 10 |
stool samples | 10 |
study shows | 10 |
rhd weak | 10 |
antibody screen | 10 |
cell types | 10 |
wild type | 10 |
significant proportion | 10 |
one study | 10 |
fulminant hepatitis | 10 |
rich plasma | 10 |
chronic infections | 10 |
whose infection | 10 |
swine hepatitis | 10 |
health problem | 10 |
kda protein | 10 |
animal viruses | 10 |
cdna clone | 10 |
hemolytic anemia | 10 |
healthy individuals | 10 |
healthy controls | 10 |
human hepatoma | 10 |
commonly used | 10 |
clinical data | 10 |
acetylesterase activity | 10 |
prevalence among | 10 |
donating blood | 10 |
latex slit | 10 |
viral population | 10 |
different countries | 10 |
mean ae | 10 |
study aims | 10 |
protease domain | 9 |
current study | 9 |
healthy donors | 9 |
human coronavirus | 9 |
discrepant results | 9 |
haemorrhagic shock | 9 |
postpartum hemorrhage | 9 |
old female | 9 |
test results | 9 |
human plasma | 9 |
acid sequence | 9 |
recent advances | 9 |
positive dat | 9 |
virus release | 9 |
mouse hepatitis | 9 |
platelet aggregation | 9 |
clinical studies | 9 |
total blood | 9 |
virus genome | 9 |
chronic adenotonsillar | 9 |
time rt | 9 |
adverse transfusion | 9 |
hemopathic patients | 9 |
tested positive | 9 |
frozen raspberries | 9 |
patient identification | 9 |
food safety | 9 |
post transfusion | 9 |
envelope protein | 9 |
hev persistence | 9 |
gel electrophoresis | 9 |
hematological patients | 9 |
evidence based | 9 |
hc group | 9 |
adenotonsillar diseases | 9 |
routine testing | 9 |
donor adverse | 9 |
well plates | 9 |
two units | 9 |
case fatality | 9 |
occupational exposure | 9 |
abo antigens | 9 |
human astrovirus | 9 |
slaughterhouse workers | 9 |
prototype sequence | 9 |
morpholino oligomers | 9 |
two samples | 9 |
finger prick | 9 |
authors declare | 9 |
virion types | 9 |
pm shift | 9 |
hypervariable region | 9 |
pcr products | 9 |
mirasol treated | 9 |
genomic organization | 9 |
sars coronavirus | 9 |
data obtained | 9 |
movement data | 9 |
confirmed positive | 9 |
hemoglobin levels | 9 |
endemic areas | 9 |
software version | 9 |
active infection | 9 |
binding domain | 9 |
human enteric | 9 |
pig kidney | 9 |
sample id | 9 |
cchfv infection | 9 |
without agitation | 9 |
vertical transmission | 9 |
agglutination technology | 9 |
clinical signs | 9 |
blood culture | 9 |
also determined | 9 |
common cause | 9 |
cytopathic effect | 9 |
rectal swabs | 9 |
platelet storage | 9 |
polyproline region | 9 |
emerging infectious | 9 |
also tested | 9 |
reverse type | 9 |
stored platelets | 9 |
dna polymerase | 9 |
transfusion support | 9 |
immunomodulatory mediators | 9 |
virus capsid | 9 |
slightly higher | 9 |
time qpcr | 9 |
prrsv infection | 9 |
zoonotic infections | 9 |
antiviral therapy | 9 |
study group | 9 |
may occur | 9 |
blood establishments | 9 |
neutralizing human | 9 |
cohort study | 9 |
reactive donors | 9 |
selection process | 9 |
abo discrepancies | 9 |
using alinity | 9 |
higher seroprevalence | 9 |
one patient | 9 |
relatively high | 9 |
unexpected antibody | 9 |
rare donor | 9 |
long term | 9 |
surveillance programmes | 9 |
cross blood | 9 |
inclusion criteria | 9 |
pregnant woman | 9 |
delayed transfusion | 9 |
donated blood | 9 |
samples obtained | 9 |
intron enhancer | 9 |
avian hev | 9 |
drug administration | 9 |
nonstructural polyprotein | 9 |
nonstructural protein | 9 |
human platelet | 9 |
analyzed using | 9 |
income countries | 9 |
mouth disease | 9 |
diverse viruses | 9 |
rbc blood | 9 |
avian influenza | 9 |
i cells | 9 |
monoclonal anti | 9 |
received ch | 9 |
environmental conditions | 9 |
different hev | 9 |
patients suffering | 9 |
hev detection | 9 |
pro domain | 9 |
negative results | 9 |
emerging zoonotic | 9 |
blood bags | 9 |
cd hematopoietic | 9 |
patients whose | 9 |
hla class | 9 |
chronic inflammation | 9 |
donation site | 9 |
group i | 9 |
current status | 9 |
epidemiological data | 9 |
rare blood | 9 |
study included | 9 |
deferral rate | 9 |
severe transfusion | 9 |
abo gene | 9 |
north america | 9 |
deferred donors | 9 |
positive result | 9 |
rh blood | 9 |
nested pcr | 9 |
mycophenolic acid | 9 |
reverse primer | 9 |
regional blood | 9 |
clinical course | 9 |
comparative study | 8 |
applied biosystems | 8 |
using spss | 8 |
forward primer | 8 |
healthy blood | 8 |
blot analysis | 8 |
transfusion strategies | 8 |
low ferritin | 8 |
protease inhibitor | 8 |
acute phase | 8 |
pig movements | 8 |
human rhinovirus | 8 |
described elsewhere | 8 |
susceptibility gene | 8 |
specimen collection | 8 |
incubation period | 8 |
abo system | 8 |
lung injury | 8 |
full length | 8 |
rhd antigen | 8 |
united arab | 8 |
bb mode | 8 |
binding assay | 8 |
will help | 8 |
positive patients | 8 |
infected pyramidal | 8 |
last donation | 8 |
first step | 8 |
causative agent | 8 |
large numbers | 8 |
neurological injury | 8 |
new blood | 8 |
latex extract | 8 |
negative blood | 8 |
hb values | 8 |
immunosuppressed patients | 8 |
may contribute | 8 |
rna replication | 8 |
dans des | 8 |
simplex virus | 8 |
frequency antigens | 8 |
dat positive | 8 |
compatibility testing | 8 |
zoonotic viruses | 8 |
positive control | 8 |
related adverse | 8 |
hev quasispecies | 8 |
patient care | 8 |
infected rats | 8 |
routine blood | 8 |
hev cdna | 8 |
patient outcomes | 8 |
variant alleles | 8 |
polyclonal anti | 8 |
full text | 8 |
negative samples | 8 |
multiplex pcr | 8 |
dna viruses | 8 |
flow cytometric | 8 |
genetic characterization | 8 |
hev sequence | 8 |
management system | 8 |
infecting humans | 8 |
days storage | 8 |
structural proteins | 8 |
virus helicase | 8 |
data collection | 8 |
blood chimerism | 8 |
thalassemia major | 8 |
hepg cells | 8 |
severe disease | 8 |
body fluids | 8 |
economic status | 8 |
sg niv | 8 |
hiv incidence | 8 |
spss software | 8 |
sigma metrics | 8 |
primer hevorf | 8 |
close contact | 8 |
variant rhd | 8 |
standard serological | 8 |
polyacrylamide gel | 8 |
pollen season | 8 |
quality indicators | 8 |
maternal plasma | 8 |
allogeneic donors | 8 |
better understanding | 8 |
prototype sequences | 8 |
homozygous mutation | 8 |
standard treatment | 8 |
bamboo rat | 8 |
pork products | 8 |
apheresis procedures | 8 |
bovine coronavirus | 8 |
body weight | 8 |
better understand | 8 |
national level | 8 |
call rates | 8 |
arab emirates | 8 |
liver cells | 8 |
molecular weight | 8 |
conserved among | 8 |
shelf life | 8 |
squ students | 8 |
gel selection | 8 |
oxygen uptake | 8 |
transmitted hepatitis | 8 |
delayed hemolytic | 8 |
functional analysis | 8 |
infection became | 8 |
also demonstrated | 8 |
allele abo | 8 |
product utilization | 8 |
may suggest | 8 |
molecular testing | 8 |
igg assay | 8 |
respiratory pathogens | 8 |
without clinical | 8 |
genotyping results | 8 |
correlation coefficient | 8 |
two patients | 8 |
transfusion events | 8 |
hospital population | 8 |
previously identified | 8 |
palatine tonsils | 8 |
natural history | 8 |
additive effect | 8 |
porcine cytomegalovirus | 8 |
apheresis donors | 8 |
swine industry | 8 |
herpes simplex | 8 |
data collected | 8 |
three years | 8 |
flow rate | 8 |
among repeat | 8 |
like protease | 8 |
progeny virions | 8 |
serological typing | 8 |
pathogen identification | 8 |
higher rates | 8 |
sid patients | 8 |
molecular methods | 8 |
genetic analysis | 8 |
hiv prevalence | 8 |
sar strain | 8 |
cost effective | 8 |
neutralizing activity | 8 |
allergic reaction | 8 |
group ii | 8 |
high seroprevalence | 8 |
rhd alleles | 8 |
measured using | 8 |
operating room | 8 |
proteolytic processing | 8 |
human blood | 8 |
polyprotein processing | 8 |
temporary deferral | 8 |
blood unit | 8 |
pcr assay | 8 |
hospital transfusion | 8 |
wnv infection | 8 |
cell free | 8 |
host immune | 8 |
data indicate | 8 |
female donor | 8 |
allogeneic blood | 8 |
limited resources | 8 |
i ii | 8 |
vaccinia virus | 8 |
gr dl | 8 |
domestic pigs | 8 |
became chronic | 8 |
blood processed | 8 |
molecular analysis | 8 |
lethal mutagenesis | 8 |
medical records | 8 |
nonstructural gene | 8 |
genus orthohepevirus | 8 |
zoonotic infection | 8 |
positive rate | 8 |
platelet cd | 8 |
two weeks | 8 |
regression analysis | 8 |
results showed | 8 |
young male | 8 |
cdna library | 8 |
endoplasmic reticulum | 8 |
hev transmission | 8 |
lactate production | 8 |
negative donors | 8 |
neurological tumours | 8 |
rat hev | 8 |
transmissible gastroenteritis | 8 |
recombinant hev | 8 |
igg positivity | 8 |
phylogenetic analyses | 8 |
reverse transcriptase | 8 |
oral iron | 8 |
genetic basis | 8 |
hev vaccine | 8 |
pig production | 8 |
per day | 8 |
positive correlation | 8 |
within min | 8 |
haemolytic disease | 8 |
ionized calcium | 8 |
hormone intake | 8 |
hev entry | 8 |
infectious dose | 8 |
maximal oxygen | 8 |
systemic reactions | 8 |
vaccine development | 8 |
hev antibody | 8 |
sialic acid | 8 |
conserved domain | 8 |
highly diverse | 8 |
prevalence antigen | 8 |
also observed | 8 |
retrospective review | 7 |
crystal forms | 7 |
reactive neutralizing | 7 |
cfu cm | 7 |
antibody specificities | 7 |
placebo group | 7 |
genome sequencing | 7 |
health issues | 7 |
biological activity | 7 |
primer extension | 7 |
hospital blood | 7 |
found positive | 7 |
irregular antibodies | 7 |
rbc exchange | 7 |
transfusion history | 7 |
human serum | 7 |
considered statistically | 7 |
bacterial infections | 7 |
transfusion sample | 7 |
inconclusive results | 7 |
storage conditions | 7 |
myeloid leukemia | 7 |
arv use | 7 |
binding pocket | 7 |
human beings | 7 |
secondary structure | 7 |
blood establishment | 7 |
multiple myeloma | 7 |
divalent cations | 7 |
lutheran glycoprotein | 7 |
neonatal alloimmune | 7 |
test units | 7 |
nat screening | 7 |
genomes project | 7 |
cv ranged | 7 |
cmnc spectra | 7 |
pig population | 7 |
zikv rna | 7 |
ml well | 7 |
rhd exons | 7 |
study using | 7 |
quality parameters | 7 |
democratic republic | 7 |
rabbit strains | 7 |
infected sf | 7 |
ferritin testing | 7 |
transmission route | 7 |
proximal promoter | 7 |
determined using | 7 |
typing discrepancy | 7 |
low prevalence | 7 |
infected cyno | 7 |
pgy group | 7 |
eye drops | 7 |
coding sequence | 7 |
drug development | 7 |
linked immunosorbent | 7 |
baculovirus expression | 7 |
hb value | 7 |
key role | 7 |
discordant results | 7 |
high number | 7 |
broad spectrum | 7 |
abbott laboratories | 7 |
low hemoglobin | 7 |
transmission via | 7 |
times per | 7 |
young children | 7 |
blood banking | 7 |
potent antiviral | 7 |
endogenous retrovirus | 7 |
hantaan virus | 7 |
iron intake | 7 |
organ failure | 7 |
rna genomes | 7 |
donation sites | 7 |
may play | 7 |
medical care | 7 |
associated cost | 7 |
inhibits hepatitis | 7 |
time point | 7 |
causes acute | 7 |
risk management | 7 |
motor cortex | 7 |
like virus | 7 |
health concern | 7 |
per procedure | 7 |
deferral period | 7 |
international society | 7 |
beta thalassemia | 7 |
rh null | 7 |
similar clinical | 7 |
higher frequency | 7 |
sucrose gradient | 7 |
one donor | 7 |
new approach | 7 |
infected pregnant | 7 |
photochemical treatment | 7 |
chemokine scavenging | 7 |
mm nacl | 7 |
medical record | 7 |
transfused units | 7 |
samples per | 7 |
ha test | 7 |
human pcs | 7 |
severe anemia | 7 |
analysed using | 7 |
hematology analyzer | 7 |
auto seds | 7 |
one sample | 7 |
ae standard | 7 |
abattoir workers | 7 |
capsid shell | 7 |
igg antibody | 7 |
higher number | 7 |
mainly due | 7 |
orf recombinant | 7 |
acute liver | 7 |
may affect | 7 |
sulfate proteoglycans | 7 |
oxidative stress | 7 |
rat hepatitis | 7 |
entry mechanism | 7 |
rodent hepacivirus | 7 |
viral loads | 7 |
core xt | 7 |
human population | 7 |
orf products | 7 |
sequence identity | 7 |
gel method | 7 |
human consumption | 7 |
negative phenotype | 7 |
prenatal testing | 7 |
allogeneic hematopoietic | 7 |
laboratory tests | 7 |
donor recruiter | 7 |
abbott alinity | 7 |
using two | 7 |
seven days | 7 |
amustaline gsh | 7 |
class ii | 7 |
ml min | 7 |
rna positive | 7 |
prf cells | 7 |
infect dis | 7 |
old woman | 7 |
square test | 7 |
adult patients | 7 |
donation attempt | 7 |
genome sequence | 7 |
care hospital | 7 |
mekong delta | 7 |
destroying enzyme | 7 |
camel meat | 7 |
pregnant donors | 7 |
prolonged storage | 7 |
transfusion within | 7 |
latex sensitization | 7 |
machine learning | 7 |
fatality rate | 7 |
increased mortality | 7 |
using flow | 7 |
host disease | 7 |
hev exposure | 7 |
serological assays | 7 |
irregular antibody | 7 |
hev isolates | 7 |
positive pigs | 7 |
expiry date | 7 |
newly identified | 7 |
coli bl | 7 |
higher prevalence | 7 |
neuralgic amyotrophy | 7 |
disease caused | 7 |
recombinant orf | 7 |
serious adverse | 7 |
several years | 7 |
written informed | 7 |
rh antigens | 7 |
organ transplantation | 7 |
age pigs | 7 |
clinically important | 7 |
mutagenic effect | 7 |
swine hev | 7 |
lassa virus | 7 |
pig movement | 7 |
binding activity | 7 |
highest risk | 7 |
decreased significantly | 7 |
male donor | 7 |
may result | 7 |
patients without | 7 |
beckman coulter | 7 |
transfusion guidelines | 7 |
serum proteins | 7 |
cell proliferation | 7 |
heavy chain | 7 |
inhibitory activity | 7 |
experimentally infected | 7 |
different sources | 7 |
health services | 7 |
subgenomic messages | 7 |
serine protease | 7 |
target sequences | 7 |
phase clinical | 7 |
platelet activation | 7 |
routine abo | 7 |
among different | 7 |
crystal structures | 7 |
free dna | 7 |
light chain | 7 |
serum il | 7 |
arachidonic acid | 7 |
virus outbreaks | 7 |
timely manner | 7 |
african descent | 7 |
pcr amplification | 7 |
accel version | 7 |
solid phase | 7 |
linear regression | 7 |
platelet additive | 7 |
incidence antigen | 7 |
risk patients | 7 |
ethics committee | 7 |
transfusion policy | 7 |
maternal rhd | 7 |
preventive measures | 7 |
dis doi | 7 |
sequences obtained | 7 |
study conducted | 7 |
cell entry | 7 |
combination therapy | 7 |
per donor | 7 |
improve patient | 7 |
manual method | 7 |
host factor | 7 |
probe sequences | 7 |
duffy blood | 7 |
studies using | 7 |
high viral | 7 |
specific immunotherapy | 7 |
significant risk | 7 |
different genotypes | 7 |
repeat reactive | 7 |
prc unit | 7 |
nipah viruses | 7 |
igg positive | 7 |
asia type | 7 |
saudi arabia | 7 |
zoonotic risk | 7 |
third trimester | 7 |
pcv infection | 7 |
cell attachment | 7 |
cyno liver | 7 |
operating procedures | 7 |
acid sequences | 7 |
coated vesicle | 7 |
consensus proposals | 7 |
genus within | 7 |
six sigma | 7 |
analysis revealed | 7 |
virus sequences | 7 |
plasma donors | 7 |
interim platelet | 7 |
hiv rr | 7 |
calculated using | 7 |
rbc donors | 7 |
chronic disease | 7 |
human enterovirus | 7 |
envelope glycoprotein | 7 |
postweaning multisystemic | 7 |
remunerated blood | 7 |
virus nonstructural | 7 |
rural areas | 7 |
next donation | 7 |
per test | 7 |
rhce ce | 7 |
plant virus | 7 |
highly pathogenic | 7 |
donation interval | 7 |
investigate whether | 7 |
tumor susceptibility | 7 |
optical density | 7 |
ferritin level | 7 |
outbreaks associated | 7 |
hev antigen | 7 |
soluble form | 7 |
results suggested | 7 |
serological evidence | 7 |
three cases | 7 |
infected blood | 7 |
rhdi hdfn | 7 |
tpe procedures | 7 |
contact dermatitis | 7 |
low level | 7 |
using commercial | 7 |
genomic sequences | 7 |
eastern mediterranean | 7 |
group matching | 7 |
secondary prevention | 7 |
fecal samples | 7 |
esterase activity | 7 |
cov macrodomain | 7 |
method using | 7 |
global burden | 7 |
avian hepatitis | 7 |
one year | 7 |
multiple transfusions | 7 |
sex hormone | 7 |
tonsil samples | 7 |
pbpc products | 7 |
done using | 7 |
may induce | 7 |
igm antibodies | 7 |
plasma freezing | 7 |
isolated using | 6 |
drug resistance | 6 |
respiratory disease | 6 |
platelet concentration | 6 |
monocyte monolayer | 6 |
also present | 6 |
two donors | 6 |
mobile blood | 6 |
hev infected | 6 |
blood centre | 6 |
one report | 6 |
monolayer assay | 6 |
genetic variants | 6 |
donor rbcs | 6 |
frequently reported | 6 |
error threshold | 6 |
pathogen detection | 6 |
past years | 6 |
green onions | 6 |
supernatant fluid | 6 |
epitope mapping | 6 |
neutralizing antibody | 6 |
also reduced | 6 |
quasispecies heterogeneity | 6 |
protein structure | 6 |
including human | 6 |
acute gastroenteritis | 6 |
abo incompatibility | 6 |
porcine cell | 6 |
protein content | 6 |
also significantly | 6 |
acceptance criteria | 6 |
id core | 6 |
recipients hepatitis | 6 |
hevea brasiliensis | 6 |
panel cells | 6 |
length genomic | 6 |
different criteria | 6 |
epidermal growth | 6 |
binding motif | 6 |
swine kidney | 6 |
thalassemia patients | 6 |
thap province | 6 |
review board | 6 |
transmission may | 6 |
serum sample | 6 |
regulatory requirements | 6 |
abo subgroups | 6 |
blood mononuclear | 6 |
surface antigen | 6 |
donors aged | 6 |
inflammatory cytokines | 6 |
compared using | 6 |
physical activity | 6 |
nat testing | 6 |
ehev particles | 6 |
based methods | 6 |
polymerase promotes | 6 |
molecular epidemiology | 6 |
current blood | 6 |
become chronic | 6 |
older age | 6 |
tube technique | 6 |
hemoglobin derivatives | 6 |
reminder message | 6 |
iron deficient | 6 |
positive impact | 6 |
known risk | 6 |
statistical significance | 6 |
small number | 6 |
niv infection | 6 |
particular interest | 6 |
protein expressed | 6 |
predictive value | 6 |
rhd el | 6 |
clinical condition | 6 |
genome encodes | 6 |
pid patients | 6 |
significant reduction | 6 |
logu ml | 6 |
null phenotype | 6 |
observational studies | 6 |
hev positive | 6 |
hh patients | 6 |
molecular mechanisms | 6 |
viral extinction | 6 |
increased cd | 6 |
frequent blood | 6 |
also included | 6 |
platelet loss | 6 |
previously published | 6 |
ec directive | 6 |
elisa kit | 6 |
molecular screening | 6 |
wb units | 6 |
apheresis collection | 6 |
endosomal membrane | 6 |
maternal antibodies | 6 |
cell transfusions | 6 |
nov outbreaks | 6 |
pxxp motif | 6 |
study suggests | 6 |
next days | 6 |
high resolution | 6 |
purified protein | 6 |
prrsv strains | 6 |
nhs blood | 6 |
rodent pegivirus | 6 |
conformational changes | 6 |
future studies | 6 |
polymerase activity | 6 |
spss version | 6 |
quality assessment | 6 |
nonhuman primate | 6 |
viruses may | 6 |
decision making | 6 |
cell reagents | 6 |
efficient cell | 6 |
using pcr | 6 |
cells infected | 6 |
studies conducted | 6 |
working group | 6 |
human respiratory | 6 |
like proteases | 6 |
level hev | 6 |
bronchitis virus | 6 |
increasing number | 6 |
synthesized rna | 6 |
study demonstrated | 6 |
nucleotide substitutions | 6 |
independently associated | 6 |
group phenotypes | 6 |
blood guide | 6 |
factor viii | 6 |
frequency antigen | 6 |
institutional review | 6 |
methylene blue | 6 |
therapeutic agent | 6 |
ferritin ng | 6 |
potent cross | 6 |
supply management | 6 |
international standard | 6 |
antiviral properties | 6 |
donation frequency | 6 |
specific primer | 6 |
positive group | 6 |
nucleotide identity | 6 |
acid residues | 6 |
positive blood | 6 |
rhd zygosity | 6 |
target effects | 6 |
study population | 6 |
flow diagram | 6 |
lower ph | 6 |
leukemia virus | 6 |
autologous donors | 6 |
future donation | 6 |
gmp mfi | 6 |
also identified | 6 |
weak positive | 6 |
antibody titer | 6 |
korean population | 6 |
like viruses | 6 |
infectious hepatitis | 6 |
included patients | 6 |
travel history | 6 |
meat products | 6 |
borne encephalitis | 6 |
transfusion models | 6 |
alt levels | 6 |
donor experience | 6 |
negative red | 6 |
hodgkin lymphoma | 6 |
acute infection | 6 |
antigen typing | 6 |
transfused platelets | 6 |
old disease | 6 |
del phenotype | 6 |
antibody concentration | 6 |
way anova | 6 |
locally acquired | 6 |
rbc alloimmunization | 6 |
eye syndrome | 6 |
consistent results | 6 |
reactive neutralization | 6 |
sequence specific | 6 |
cynomolgus macaques | 6 |
high specificity | 6 |
viral membrane | 6 |
central blood | 6 |
surface proteins | 6 |
hev macrodomain | 6 |
allergic patients | 6 |
endemic regions | 6 |
erythrocyte antibody | 6 |
detection methods | 6 |
serologically apparent | 6 |
analyses showed | 6 |
thank dr | 6 |
virus families | 6 |
washed three | 6 |
red crescent | 6 |
cells transfected | 6 |
care unit | 6 |
transfusion platelet | 6 |
blind placebo | 6 |
stranded positive | 6 |
virus neutralization | 6 |
des cellules | 6 |
primarily transmitted | 6 |
htl epitopes | 6 |
social media | 6 |
also reported | 6 |
structural basis | 6 |
two viruses | 6 |
temporarily deferred | 6 |
stored sheep | 6 |
attachment glycoprotein | 6 |
abo discrepancy | 6 |
splice junctions | 6 |
cd gene | 6 |
rhd protein | 6 |
three open | 6 |
novel virus | 6 |
human samples | 6 |
hev life | 6 |
blind passage | 6 |
young blood | 6 |
donor pool | 6 |
routinely used | 6 |
among donors | 6 |
null individuals | 6 |
chain shuffling | 6 |
hdfn due | 6 |
platelet apheresis | 6 |
closed system | 6 |
care system | 6 |
evaluated using | 6 |
rbc alloantibodies | 6 |
following criteria | 6 |
regulatory framework | 6 |
spectrin matrix | 6 |
using automated | 6 |
surgical procedures | 6 |
high expression | 6 |
uk blood | 6 |
hev helicase | 6 |
incident hiv | 6 |
lifestyle behaviors | 6 |
cd expression | 6 |
alloantibody formation | 6 |
kir dl | 6 |
igm igg | 6 |
component therapy | 6 |
repeat blood | 6 |
rh antigen | 6 |
human bocavirus | 6 |
vero cells | 6 |
viral life | 6 |
urgent need | 6 |
yeast two | 6 |
serum levels | 6 |
first blood | 6 |
cell antibodies | 6 |
data demonstrate | 6 |
inhibits viral | 6 |
available data | 6 |
trypsin cleavage | 6 |
hev transcription | 6 |
infected humans | 6 |
farm hev | 6 |
hydrogen bond | 6 |
high sequence | 6 |
significantly different | 6 |
viral clearance | 6 |
variant allele | 6 |
accession number | 6 |
inventory management | 6 |
platelet autoantibodies | 6 |
containing receptors | 6 |
sequencing detected | 6 |
granulocyte transfusion | 6 |
closely monitored | 6 |
enveloped hev | 6 |
medical history | 6 |
per well | 6 |
sequence data | 6 |
may lead | 6 |
rh kell | 6 |
agricultural workers | 6 |
higher hev | 6 |
protein band | 6 |
protein interaction | 6 |
variable domain | 6 |
typing discrepancies | 6 |
clerical errors | 6 |
antifungal activity | 6 |
cell fusion | 6 |
prevalence rate | 6 |
orf capsid | 6 |
enzyme activity | 6 |
sporadic acute | 6 |
hepatitis worldwide | 6 |
significant decrease | 6 |
nucleoside analogue | 6 |
gel card | 6 |
workers exposed | 6 |
donors increased | 6 |
spth cells | 6 |
specific anti | 6 |
per sample | 6 |
safe transfusion | 6 |
novel genotype | 6 |
deferral reasons | 6 |
gastroenteritis virus | 6 |
active hev | 6 |
storage duration | 6 |
apparently healthy | 6 |
directive ec | 6 |
th donation | 6 |
case study | 6 |
fetal blood | 6 |
blood bag | 6 |
assure consistent | 6 |
samples showed | 6 |
dubai blood | 6 |
architect anti | 6 |
zoonotic pathogens | 6 |
analysis using | 6 |
agarose gel | 6 |
medical treatment | 6 |
leukocyte reduction | 6 |
positive direct | 6 |
storage lesion | 6 |
cell donors | 6 |
takes place | 6 |
infection may | 6 |
host tropism | 6 |
tested samples | 6 |
fresenius kabi | 6 |
prbc unit | 6 |
three groups | 6 |
human pathogens | 6 |
disease spread | 6 |
ml kg | 6 |
high levels | 6 |
fold higher | 6 |
old transfusion | 6 |
treatment option | 6 |
fusion protein | 6 |
antibody library | 6 |
premedication rate | 6 |
cellular receptors | 6 |
manual tube | 6 |
reported cases | 6 |
negative women | 6 |
group genes | 6 |
continuous flow | 6 |
mechanisms underlying | 6 |
hb increment | 6 |
return rates | 6 |
nucleotide synthesis | 6 |
scid mice | 6 |
transfected cells | 6 |
emergency uncrossmatched | 6 |
expression level | 6 |
donation screening | 6 |
donor typing | 6 |
human viruses | 6 |
strains circulating | 6 |
exceptionally potent | 6 |
hcv infection | 6 |
molecular cloning | 6 |
taken together | 6 |
transcription factors | 6 |
study found | 6 |
transfusion transmission | 6 |
study provides | 6 |
acute infections | 6 |
low haemoglobin | 6 |
megakaryocytes differentiation | 6 |
species orthohepevirus | 6 |
donor lapse | 6 |
january st | 6 |
respiratory secretions | 6 |
well established | 6 |
concentrates derived | 6 |
theraflex mb | 6 |
ingoing closeness | 6 |
also detected | 6 |
spike protein | 6 |
enteric virus | 6 |
help us | 6 |
mean ce | 6 |
ppmo hp | 6 |
transfusion laboratory | 6 |
low ph | 6 |
dce dce | 6 |
epitope specific | 6 |
potent inhibitor | 6 |
du virus | 6 |
frozen berries | 6 |
aa residues | 6 |
performed according | 6 |
type del | 6 |
average values | 6 |
although hev | 6 |
specific treatment | 6 |
distal ribose | 6 |
persistent postpartum | 6 |
inhibit hev | 6 |
cervical mucus | 6 |
endemic countries | 6 |
neo iris | 6 |
culture supernatant | 6 |
multiepitope construct | 6 |
rattus norvegicus | 6 |
hrv serotypes | 6 |
male recipients | 6 |
phase i | 6 |
foodborne illness | 6 |
virus presence | 6 |
blood demand | 6 |
significantly decreased | 6 |
neutralising antibodies | 6 |
cdna libraries | 6 |
electron microscopic | 6 |
ordering prc | 6 |
group ab | 6 |
density maps | 6 |
surface area | 6 |
rhd beadchip | 6 |
hiv follow | 6 |
serological techniques | 6 |
acute hev | 6 |
secondary testing | 6 |
human cases | 6 |
homology model | 6 |
harvesting areas | 6 |
marrow donors | 6 |
hepatitis viruses | 6 |
irradiated rbcs | 6 |
complex therapy | 6 |
repeated blood | 6 |
buccal swab | 6 |
caliciviridae family | 6 |
virus among | 6 |
hla antibody | 6 |
ottingen minipigs | 6 |
cell ratios | 6 |
artificial tears | 6 |
electronic medical | 6 |
naturally infected | 6 |
donation attempts | 6 |
typing results | 6 |
deer meat | 6 |
adenotonsillar tissues | 6 |
repeatedly reactive | 5 |
different red | 5 |
like particle | 5 |
nine patients | 5 |
barr virus | 5 |
lipid envelope | 5 |
rna using | 5 |
without compromising | 5 |
allele frequency | 5 |
gel coombs | 5 |
great potential | 5 |
specific weight | 5 |
cell activation | 5 |
nucleotide polymorphism | 5 |
experimental infection | 5 |
seasonal variation | 5 |
chimeric antigen | 5 |
evaluation data | 5 |
donation patterns | 5 |
platelet antibodies | 5 |
answered yes | 5 |
facilitate hev | 5 |
hcv screening | 5 |
human biopl | 5 |
immunized women | 5 |
received blood | 5 |
rattus tanezumi | 5 |
animal origin | 5 |
studies indicate | 5 |
immucor bioarray | 5 |
serologic testing | 5 |
drug repurposing | 5 |
lamina propria | 5 |
latex exposure | 5 |
antibody tests | 5 |
time blood | 5 |
highly variable | 5 |
previous transfusion | 5 |
chymotrypsin like | 5 |
serologic typing | 5 |
cell tropism | 5 |
dizygotic twins | 5 |
higher concentrations | 5 |
study reports | 5 |
full genome | 5 |
epithelial cell | 5 |
significant variation | 5 |
autoimmune haemolytic | 5 |
terminal region | 5 |
id rhd | 5 |
positive cases | 5 |
standard procedures | 5 |
hfe mutations | 5 |
healthcare system | 5 |
high endemicity | 5 |
immunosorbent assay | 5 |
serum alt | 5 |
pgy physicians | 5 |
mammalian cell | 5 |
inflammatory cytokine | 5 |
transfusion centers | 5 |
acid testing | 5 |
gastroenteritis outbreaks | 5 |
acute lung | 5 |
ml whole | 5 |
heart failure | 5 |
rna negative | 5 |
one serotype | 5 |
results indicated | 5 |
contaminated blood | 5 |
international users | 5 |
sz group | 5 |
one week | 5 |
viruses infecting | 5 |
prevention strategies | 5 |
i interferon | 5 |
complement activation | 5 |
human rhinoviruses | 5 |
immature hastv | 5 |
ka ks | 5 |
acute hbv | 5 |
infectious bronchitis | 5 |
recovered individuals | 5 |
rodent species | 5 |
next best | 5 |
free system | 5 |
function testing | 5 |
monophosphate dehydrogenase | 5 |
mental illness | 5 |
two phases | 5 |
liver cirrhosis | 5 |
bb tm | 5 |
still unknown | 5 |
bat species | 5 |
southeast asia | 5 |
additional evidence | 5 |
inactivation treatment | 5 |
bovine serum | 5 |
infectious hev | 5 |
gene therapy | 5 |
rat hepaciviruses | 5 |
clinical outcomes | 5 |
post donation | 5 |
allergic diseases | 5 |
dry eye | 5 |
japanese encephalitis | 5 |
serological findings | 5 |
virus encephalitis | 5 |
cap structure | 5 |
inosine monophosphate | 5 |
among patients | 5 |
first line | 5 |
high hev | 5 |
ferret serum | 5 |
existing data | 5 |
inhibition assay | 5 |
western europe | 5 |
warm aiha | 5 |
gene editing | 5 |
hav igm | 5 |
healthy subjects | 5 |
middle cerebral | 5 |
antiviral adp | 5 |
stromal cells | 5 |
hev virion | 5 |
rhd status | 5 |
swiss red | 5 |
published studies | 5 |
african blood | 5 |
vast majority | 5 |
pcv antigen | 5 |
slightly lower | 5 |
cross sectional | 5 |
incidence antigens | 5 |
increased number | 5 |
million infections | 5 |
transfusion indications | 5 |
leukaemia virus | 5 |
transcription factor | 5 |
hybrid genes | 5 |
several countries | 5 |
healthcare staff | 5 |
changes observed | 5 |
last transfusion | 5 |
elimination half | 5 |
rc societies | 5 |
ready gene | 5 |
blood conservation | 5 |
th hour | 5 |
higher binding | 5 |
bleeding prevention | 5 |
titration end | 5 |
igg titers | 5 |
type iv | 5 |
weak subgroups | 5 |
substrate concentration | 5 |
pediatric population | 5 |
normal blood | 5 |
detection limit | 5 |
pegfp vector | 5 |
virus assembly | 5 |
compatible units | 5 |
viruses detected | 5 |
gpiib iiia | 5 |
auckland island | 5 |
plasma donation | 5 |
automated system | 5 |
management systems | 5 |
transplant tpe | 5 |
lymph node | 5 |
mediated endocytosis | 5 |
changed significantly | 5 |
rbc chemokine | 5 |
structural gene | 5 |
confirmatory tests | 5 |
transfused blood | 5 |
storage lesions | 5 |
serological methods | 5 |
ribavirin inhibits | 5 |
eligible donors | 5 |
paediatric cardiac | 5 |
detected hev | 5 |
life threatening | 5 |
fluorescence intensity | 5 |
younger age | 5 |
rbc antigens | 5 |
axonal terminals | 5 |
epidemiological study | 5 |
technical assistance | 5 |
dietary iron | 5 |
false reactive | 5 |
via contaminated | 5 |
signal sequence | 5 |
intercept tm | 5 |
intercept treatment | 5 |
risk behaviours | 5 |
well studied | 5 |
seasonal variations | 5 |
seasonal pattern | 5 |
positive antibody | 5 |
standard operating | 5 |
fulminant liver | 5 |
passenger leukocytes | 5 |
staphylococcus aureus | 5 |
antiviral strategy | 5 |
pc supernatant | 5 |
samples containing | 5 |
controlled study | 5 |
medium containing | 5 |
ml per | 5 |
medication question | 5 |
high rates | 5 |
pig thyroid | 5 |
vertically transmitted | 5 |
test period | 5 |
platelet unit | 5 |
donation deferral | 5 |
frozen strawberries | 5 |
immunocompromised individuals | 5 |
diagnostic testing | 5 |
ige antibodies | 5 |
donor panel | 5 |
within months | 5 |
entry process | 5 |
naip regions | 5 |
depressive symptoms | 5 |
per cell | 5 |
bovine tuberculosis | 5 |
length orf | 5 |
zinc salts | 5 |
immune cells | 5 |
virus species | 5 |
occupational risk | 5 |
wild rats | 5 |
attending population | 5 |
ab rna | 5 |
different kinds | 5 |
swine hemagglutinating | 5 |
important cause | 5 |
negative group | 5 |
line treatment | 5 |
statistical methods | 5 |
large outbreak | 5 |
donors received | 5 |
ebola virus | 5 |
transgenic pigs | 5 |
length genome | 5 |
least two | 5 |
transfusion chain | 5 |
collection using | 5 |
blood separation | 5 |
zoonotic potential | 5 |
elution test | 5 |
prospective observational | 5 |
related acute | 5 |
cerebral artery | 5 |
prototype regions | 5 |
transmembrane envelope | 5 |
log reduction | 5 |
protein sequences | 5 |
close proximity | 5 |
standard dose | 5 |
extended storage | 5 |
may serve | 5 |
reveos device | 5 |
capping enzyme | 5 |
existing liver | 5 |
positive strand | 5 |
venous hemoglobin | 5 |
fold increase | 5 |
platelet derived | 5 |
farmed bamboo | 5 |
infection status | 5 |
accession numbers | 5 |
seroprevalence among | 5 |
search terms | 5 |
docking score | 5 |
per month | 5 |
blood count | 5 |
studies will | 5 |
four major | 5 |
donate plasma | 5 |
clinical efficacy | 5 |
fully sheeted | 5 |
using standard | 5 |
rbc antibodies | 5 |
common antibody | 5 |
staphylococcus epidermidis | 5 |
venous blood | 5 |
low iron | 5 |
virus attachment | 5 |
lesser extent | 5 |
basophil activation | 5 |
postmenopausal women | 5 |
rh phenotype | 5 |
study revealed | 5 |
abo antigen | 5 |
antibody mediated | 5 |
tropical regions | 5 |
abattoir survey | 5 |
using samples | 5 |
specific monoclonal | 5 |
hav infection | 5 |
weak agglutination | 5 |
neg rbcs | 5 |
age limit | 5 |
volume processed | 5 |
virus load | 5 |
weaned pigs | 5 |
working party | 5 |
alkaline phosphatase | 5 |
abbott architect | 5 |
previously tested | 5 |
literature data | 5 |
binding affinities | 5 |
human enteroviruses | 5 |
elisa kits | 5 |
donor age | 5 |
iron content | 5 |
additional group | 5 |
laboratory parameters | 5 |
sindbis virus | 5 |
positive anti | 5 |
higher platelet | 5 |
oncology patients | 5 |
window period | 5 |
gastroenteritis associated | 5 |
antibody negative | 5 |
dat negative | 5 |
pathogen microarray | 5 |
latex allergens | 5 |
tests performed | 5 |
respiratory infections | 5 |
animal model | 5 |
viral populations | 5 |
times higher | 5 |
relatively low | 5 |
significant effect | 5 |
among health | 5 |
sequencing analysis | 5 |
vary significantly | 5 |
well known | 5 |
virus isolation | 5 |
reference lab | 5 |
observed within | 5 |
sh domains | 5 |
significant association | 5 |
antiviral effects | 5 |
serum igg | 5 |
vaccine candidate | 5 |
also seen | 5 |
social network | 5 |
control units | 5 |
novel viral | 5 |
enveloped hepatitis | 5 |
following stimulation | 5 |
transfusion centre | 5 |
matching strategies | 5 |
hydrophobic interactions | 5 |
risk analysis | 5 |
animal husbandry | 5 |
patient population | 5 |
common causes | 5 |
antibody specificity | 5 |
tract infections | 5 |
increased significantly | 5 |
coding sequences | 5 |
data points | 5 |
virus strain | 5 |
plasma donations | 5 |
different cell | 5 |
derived cells | 5 |
gata binding | 5 |
cell epitopes | 5 |
trauma centers | 5 |
assessed using | 5 |
haemagglutinating encephalomyelitis | 5 |
positive signals | 5 |
oxygen delivery | 5 |
transfusion process | 5 |
cellular gtp | 5 |
lipid membrane | 5 |
related mortality | 5 |
wnv risk | 5 |
viral outbreaks | 5 |
stranded dna | 5 |
kinetic parameters | 5 |
mean serum | 5 |
food items | 5 |
international collaboration | 5 |
hepatic failure | 5 |
severe anaemia | 5 |
matched rbc | 5 |
positive patient | 5 |
viruses doi | 5 |
viral detection | 5 |
bile samples | 5 |
tcid ml | 5 |
donor group | 5 |
viruses present | 5 |
overall bsms | 5 |
culture medium | 5 |
side chain | 5 |
protein may | 5 |
retention rate | 5 |
lutheran blood | 5 |
st day | 5 |
patients presented | 5 |
occupational health | 5 |
students reported | 5 |
fulminant hepatic | 5 |
mirasol prt | 5 |
adverse donor | 5 |
wide variety | 5 |
derived platelets | 5 |
national center | 5 |
rhd allele | 5 |
prrsv rna | 5 |
therapy options | 5 |
noninvasive prenatal | 5 |
hiv reactive | 5 |
data processing | 5 |
two major | 5 |
current prevalence | 5 |
virus genomes | 5 |
food products | 5 |
dependent pathway | 5 |
compassionate use | 5 |
rhd expression | 5 |
reduction technologies | 5 |
applicant donors | 5 |
platelet quality | 5 |
hydrolase activity | 5 |
platelet immunology | 5 |
testing results | 5 |
healthy adults | 5 |
abo grouping | 5 |
hiv residual | 5 |
phylogenetic trees | 5 |
muscle tissue | 5 |
severe thrombocytopenia | 5 |
whitney test | 5 |
viral infectivity | 5 |
cell populations | 5 |
sheep prbcs | 5 |
zoonotic disease | 5 |
thalassaemia patients | 5 |
apheresis cd | 5 |
tpc prior | 5 |
prophylactic platelet | 5 |
recovery process | 5 |
collection efficiency | 5 |
thai blood | 5 |
mediterranean region | 5 |
hbs level | 5 |
million symptomatic | 5 |
widely distributed | 5 |
cellular therapy | 5 |
plasmapheresis donors | 5 |
post iv | 5 |
little evidence | 5 |
critically ill | 5 |
rhd xt | 5 |
virus isolated | 5 |
users considered | 5 |
donors showed | 5 |
year old | 5 |
large volume | 5 |
clinical outcome | 5 |
four hev | 5 |
molecular mass | 5 |
rna synthesis | 5 |
virus stocks | 5 |
outbreaks linked | 5 |
still limited | 5 |
sheep prbc | 5 |
later study | 5 |
island pigs | 5 |
autoimmune hemolytic | 5 |
virus infectivity | 5 |
events reported | 5 |
primary human | 5 |
assisted assignment | 5 |
viral polymerase | 5 |
complex structures | 5 |
flow cytometer | 5 |
neutralization assays | 5 |
provocation tests | 5 |
highly similar | 5 |
rhd rhd | 5 |
high quality | 5 |
world population | 5 |
hev viremia | 5 |
ill children | 5 |
south asia | 5 |
automated systems | 5 |
adverse effect | 5 |
two hev | 5 |
blood flow | 5 |
using anti | 5 |
positive reactions | 5 |
studies included | 5 |
serological investigations | 5 |
serotype level | 5 |
sheet domain | 5 |
gene product | 5 |
sequencing panel | 5 |
practice guidelines | 5 |
density gradient | 5 |
related antibody | 5 |
rna plant | 5 |
high lactate | 5 |
three blood | 5 |
platelet membrane | 5 |
envelope proteins | 5 |
also occur | 5 |
interferon induction | 5 |
recent findings | 5 |
platelet donors | 5 |
single vendor | 5 |